loading
Cardiff Oncology Inc stock is traded at $3.89, with a volume of 999.12K. It is down -5.43% in the last 24 hours and up +26.29% over the past month. Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$4.14
Open:
$4.15
24h Volume:
999.12K
Relative Volume:
0.86
Market Cap:
$259.45M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-4.1828
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
-8.53%
1M Performance:
+26.29%
6M Performance:
+14.81%
1Y Performance:
+65.54%
1-Day Range:
Value
$3.84
$4.1866
1-Week Range:
Value
$3.73
$4.52
52-Week Range:
Value
$2.01
$5.6395

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name
Name
Cardiff Oncology Inc
Name
Phone
858-952-7570
Name
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Name
Employee
33
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
CRDF's Discussions on Twitter

Compare CRDF with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CRDF
Cardiff Oncology Inc
3.90 285.40M 488.00K -41.44M -31.47M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
467.67 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.06 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
592.49 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
292.01 31.91B 3.81B -644.79M -669.77M -6.24

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-08-25 Initiated Ladenburg Thalmann Buy
Jun-24-25 Initiated Jefferies Hold
Sep-06-24 Initiated Craig Hallum Buy
Jan-05-22 Initiated William Blair Outperform
Dec-08-21 Initiated Robert W. Baird Outperform
Aug-09-21 Resumed Maxim Group Buy
Oct-22-20 Initiated H.C. Wainwright Buy
Oct-08-20 Initiated Piper Sandler Overweight
View All

Cardiff Oncology Inc Stock (CRDF) Latest News

pulisher
Jul 24, 2025

What analysts say about Cardiff Oncology Inc. stockExplosive capital appreciation - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Is Cardiff Oncology Inc. a good long term investmentRapidly expanding wealth - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Cardiff Oncology Inc. Stock Analysis and ForecastExplosive trading opportunities - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Cardiff Oncology Inc. stock priceFast-track wealth growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What makes Cardiff Oncology Inc. stock price move sharplyFree Day Trading Recommendations - Newser

Jul 22, 2025
pulisher
Jul 18, 2025

Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term (NASDAQ:CRDF) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 15, 2025

How Cardiff Oncology Inc. stock performs during market volatilityHigh Return Setup Scanner - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Cardiff Oncology Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Cardiff Oncology (CRDF) Initiated with a Buy at Ladenburg Thalmann & Co. - The Globe and Mail

Jul 11, 2025
pulisher
Jul 11, 2025

Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH - Defense World

Jul 11, 2025
pulisher
Jul 11, 2025

Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $11.70 - Defense World

Jul 11, 2025
pulisher
Jul 09, 2025

Cardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + Paclitaxel - MSN

Jul 09, 2025
pulisher
Jul 08, 2025

Cardiff Oncology stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com Canada

Jul 08, 2025
pulisher
Jul 08, 2025

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

International Business Times - FinancialContent

Jul 08, 2025
pulisher
Jul 03, 2025

Cardiff Oncology Up 16%, Insider Buyers Are Up 35% - simplywall.st

Jul 03, 2025
pulisher
Jul 03, 2025

While institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the most - Yahoo Finance

Jul 03, 2025
pulisher
Jun 27, 2025

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha

Jun 27, 2025
pulisher
Jun 26, 2025

Cardiff Oncology Holds Annual Stockholders Meeting 2025 - TipRanks

Jun 26, 2025
pulisher
Jun 24, 2025

Jefferies Initiates Coverage on Cardiff Oncology (CRDF) with Hol - GuruFocus

Jun 24, 2025
pulisher
Jun 24, 2025

Cardiff Oncology (CRDF) Begins Coverage With Hold Rating from Jefferies | CRDF Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 24, 2025

This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga

Jun 24, 2025
pulisher
Jun 24, 2025

Cardiff Oncology stock initiated at Hold by Jefferies on early data concerns - Investing.com

Jun 24, 2025
pulisher
Jun 19, 2025

Market Overreaction to Cardiff Oncology's Data Delay Presents a Rare Buying Opportunity - AInvest

Jun 19, 2025
pulisher
Jun 18, 2025

Cardiff Oncology (CRDF) Stock Reacts to Delayed Clinical Data Up - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cardiff Oncology falls after naming new medical chief ahead of key trial readout - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

CRDF Set to Release Key Clinical Data Amid Leadership Changes | CRDF Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Cardiff Oncology (CRDF) Welcomes New Chief Medical Officer | CRD - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Offic - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Cardiff Oncology (CRDF) Shares Drop 11% After Leadership Change - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer - MarketScreener

Jun 17, 2025

Cardiff Oncology Inc Stock (CRDF) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Cardiff Oncology Inc Stock (CRDF) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Levine James E.
Chief Financial Officer
Dec 18 '24
Buy
5.00
2,400
12,000
67,716
Levine James E.
Chief Financial Officer
Dec 16 '24
Buy
3.83
2,564
9,820
62,564
TANNENBAUM RENEE P
Director
Dec 12 '24
Buy
3.42
10,000
34,224
20,000
PACE GARY W
Director
Dec 11 '24
Buy
2.60
350,115
910,299
1,047,876
PACE GARY W
Director
Dec 11 '24
Buy
2.60
11,500
29,900
1,059,376
$23.29
price down icon 1.74%
$36.50
price up icon 0.00%
$103.56
price down icon 0.03%
$27.38
price down icon 0.69%
$113.86
price down icon 0.68%
biotechnology ONC
$288.37
price down icon 2.39%
Cap:     |  Volume (24h):